文献速递重症综合管理与镇静镇痛

ICU谵妄患者出院后功能状态:AID-ICU试验1年随访

Functional Status After Delirium in the ICU: A 1-Year Follow-Up of the Agents Intervening Against Delirium in the ICU (AID-ICU) Trial.
PubMed 文献 · Crit Care Med · 2025-08-19
一句话结论成人ICU谵妄患者中,氟哌啶醇与安慰剂相比在1年功能状态各量表上均无统计学显著差异,但估计值不确定性大,不能排除临床重要差异。

这是AID-ICU随机安慰剂对照盲法试验的预设1年随访,纳入丹麦3个中心632例成人ICU谵妄患者。1年时氟哌啶醇组与安慰剂组在Lawton-Brody IADL、Barthel-20 ADL、临床衰弱量表(CFS)和握力上的校正均数差分别为0.1(95%CI -0.5至0.7)、0.2(95%CI -1.3至1.7)、0.0(95%CI -0.4至0.5)和-2.9(95%CI -7.1至1.2),均无统计学显著差异。作者结论认为氟哌啶醇与安慰剂相比未导致1年功能状态的统计学显著差异,但因估计值不确定性,不能排除临床重要差异。

要点

  • 成人ICU谵妄患者中,氟哌啶醇组与安慰剂组1年IADL校正均数差0.1(95%CI -0.5至0.7;p=0.687),无统计学显著差异。
  • 1年Barthel-20 ADL校正均数差0.2(95%CI -1.3至1.7;p=0.773),CFS校正均数差0.0(95%CI -0.4至0.5;p=0.862),均无统计学显著差异。
  • 1年握力校正均数差-2.9(95%CI -7.1至1.2;p=0.175),无统计学显著差异。
  • 作者结论:氟哌啶醇与安慰剂相比未导致1年功能状态的统计学显著差异,但因估计值不确定性,不能排除临床重要差异。

适用人群与场景

  • 纳入AID-ICU试验的成人ICU谵妄患者,来自丹麦3个中心,共632例。
  • 1年随访时氟哌啶醇组75例、安慰剂组69例可获得随访数据。

研究设计与关键结果

  • 研究类型:随机、安慰剂对照、盲法AID-ICU试验的预设1年随访。
  • 样本量:丹麦3个中心共632例成人ICU谵妄患者,1年随访时氟哌啶醇组75例、安慰剂组69例可获得数据。
  • 干预与对照:氟哌啶醇 vs 安慰剂。
  • 主要终点结果:1年时氟哌啶醇组与安慰剂组校正均数差为IADL 0.1(95%CI -0.5至0.7;p=0.687)、ADL 0.2(95%CI -1.3至1.7;p=0.773)、CFS 0.0(95%CI -0.4至0.5;p=0.862)、握力-2.9(95%CI -7.1至1.2;p=0.175),均无统计学显著差异。
  • 随访方式:28.5%(41/144)的应答者通过电话完成随访;4.2%(6/144)由亲属代答问卷。
  • 数据管理:死亡者赋最差值,缺失数据采用多重插补;结果校正年龄和性别。

证据类型、等级与局限

  • 证据类型:随机、安慰剂对照、盲法试验的预设1年随访。
  • 局限:作者指出因估计值不确定性,不能排除临床重要差异。

对床旁实践的改变

  • 作者结论:成人ICU谵妄患者中氟哌啶醇与安慰剂相比未导致1年功能状态的统计学显著差异,但因估计值不确定性,不能排除临床重要差异。

指南或共识出处

  • Agents Intervening Against Delirium in the ICU(AID-ICU)试验

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To assess the effect of haloperidol compared with placebo on functional status in adult ICU patients with delirium, 1 year after inclusion in the Agents Intervening against Delirium in the ICU (AID-ICU) trial.

DESIGN: This was a preplanned 1-year follow-up of the randomized, placebo-controlled, blinded AID-ICU trial.

SETTING AND PATIENTS: A total of 632 Danish patients enrolled in the AID-ICU trial at three selected Danish sites.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Functional status was evaluated using the Lawton-Brody Instrumental Activities of Daily Living (IADL) score, the Barthel-20 Activities of Daily Living (ADL) score, the Clinical Frailty Scale (CFS), and grip strength. Nonsurvivors were assigned the worst possible values, and missing data were managed with multiple imputation. Results were presented as mean differences and ratios of means with 95% CIs, adjusted for age, and sex. Of the original cohort of 632 patients enrolled in the AID-ICU trial at the three Danish sites, 75 participants in the haloperidol group, and 69 in the placebo group were available for follow-up. In 28.5% of responders (41/144), follow-up was performed by telephone. The proportion of relatives answering the questionnaire at 1-year follow-up on behalf of the participants was 4.2% (6/144). At 1 year, the adjusted mean differences between IADL, ADL, CFS, and grip strength in the haloperidol and placebo group were 0.1 (95% CI, -0.5 to 0.7; p = 0.687), 0.2 (95% CI, -1.3 to 1.7; p = 0.773), 0.0 (95% CI, -0.4 to 0.5; p = 0.862), and -2.9 (95% CI, -7.1 to 1.2; p = 0.175), respectively.

CONCLUSIONS: Among adult ICU patients with delirium, treatment with haloperidol vs. placebo did not result in statistically significant differences in functional status at 1-year follow-up. However, due to the uncertainty of the estimates, clinically important differences cannot be excluded.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Poulsen LM, Mortensen CB, Andersen-Ranberg NC, et al. Functional Status After Delirium in the ICU: A 1-Year Follow-Up of the Agents Intervening Against Delirium in the ICU (AID-ICU) Trial. Crit Care Med. 2025. PMID: 40826312. doi:10.1097/CCM.0000000000006842

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。